2025 China Anti-Retroviral Drugs Revenue Opportunities Report
Description
The 2025 China Anti-Retroviral Drugs Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antiretroviral (ARV) drug market in China include Shanghai Desano Biopharmaceuticals, Gilead Sciences, GlaxoSmithKline (GSK), and several local generic manufacturers. Shanghai Desano Biopharmaceuticals is notable as the first domestic producer of combination ARV drugs such as didanosine, stavudine, and nevirapine, significantly reducing drug costs to a fraction of imported equivalents and expanding access within China. Gilead Sciences is a major global ARV manufacturer, with products like Truvada (approved in China for pre-exposure prophylaxis) and other HIV treatments included in the national reimbursement list, reflecting its strong market presence and partnership with Chinese health authorities. GSK recently introduced dolutegravir (Tivicay), an integrase inhibitor recommended as first-line treatment globally and approved by the China Food and Drug Administration in 2016, with strategies to offer the drug at low prices.
Additionally, China benefits from several local generic pharmaceutical manufacturers producing inexpensive first-line ARV drugs (didanosine, stavudine, zidovudine, nevirapine, indinavir), which constitute the backbone of the national free antiretroviral treatment program initiated in 2004. These firms provide generic ARVs at approximately one-tenth the price of imported drugs, helping to dramatically reduce costs and expand nationwide access under government policies like “Four Frees and One Care”. However, challenges remain regarding second-line drug availability and treatment options due to patent and cost issues, with international firms continuing to play a critical role in introducing newer drugs like dolutegravir and tenofovir.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antiretroviral (ARV) drug market in China include Shanghai Desano Biopharmaceuticals, Gilead Sciences, GlaxoSmithKline (GSK), and several local generic manufacturers. Shanghai Desano Biopharmaceuticals is notable as the first domestic producer of combination ARV drugs such as didanosine, stavudine, and nevirapine, significantly reducing drug costs to a fraction of imported equivalents and expanding access within China. Gilead Sciences is a major global ARV manufacturer, with products like Truvada (approved in China for pre-exposure prophylaxis) and other HIV treatments included in the national reimbursement list, reflecting its strong market presence and partnership with Chinese health authorities. GSK recently introduced dolutegravir (Tivicay), an integrase inhibitor recommended as first-line treatment globally and approved by the China Food and Drug Administration in 2016, with strategies to offer the drug at low prices.
Additionally, China benefits from several local generic pharmaceutical manufacturers producing inexpensive first-line ARV drugs (didanosine, stavudine, zidovudine, nevirapine, indinavir), which constitute the backbone of the national free antiretroviral treatment program initiated in 2004. These firms provide generic ARVs at approximately one-tenth the price of imported drugs, helping to dramatically reduce costs and expand nationwide access under government policies like “Four Frees and One Care”. However, challenges remain regarding second-line drug availability and treatment options due to patent and cost issues, with international firms continuing to play a critical role in introducing newer drugs like dolutegravir and tenofovir.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
